DeBere will actively invest and organise investment syndicate with pedigree institutional Venture Capitalists and Corporate Partners. We will add strategic value across the lifecycle of the company, facilitating fundraising to exit.
TargaGenix – ($15m Round B) – Oncology
Developing novel therapeutics addressing unmet medical needs for the treatment of cancer.
Platform Imaging, LLC is a development stage company focused on completing the commercialization of the Visibot Visualization System. Visibot is a visualization system for minimally invasive surgery (MIS) based on licensed IP from Columbia University.
MannBio Pathfinder – ($150m) – Hybrid Crossover
Detact Diagnostics™ ($25m) has developed a novelle and disruptive patented bacterial detection platform/technique, that is truly innovative, highly sensitive, specific and fast, that lends itself to application development in healthcare and food. – how it works
β Cat Pharma ($25m) – Improving Cancer Treatment by Developing Novel Drug Therapies, Targeting CANCER STEM CELL PATHWAYS – the Critical Cancer Pathways Involved in Drug Resistance and Metastatic Disease
BioMarker Strategies – has developed proprietary cancer diagnostics systems which allow for targeted drug development and treatment selection for patients with solid tumor malignancies through personalized medicines.
Biovotion is a leading wearable physiology monitoring company and provides integrated solutions with connected hardware, value-added data analytics and monitoring services.
Integrity Applications – Israel and New York-based firm, traded OTC IGAP has developed a completely non-invasive glucose monitor for Type II diabetics and those with pre-diabetic conditions. The device utilizes a patented combination of ultrasonic, electromagnetic, and thermal technologies which measure three distinct criteria to provide a glucose measurement.
New Horizons Pharma applies the ALDH2 enzyme towards treatment of acute alcohol-related diseases: alcohol poisoning, alcohol-disulfiram reaction (DER), disulfiram like reaction and Asian flush.
Veriskin has a revolutionary Truscore device capable of detecting skin cancers during first examination in 2 minutes – non invasive and does not require specialistic evaluation from dermathologist
Securities offered through B.A Securities. Member FINRA/SIPC